{'fraction_non_alphanumeric': 0.03941908713692946, 'fraction_numerical': 0.006224066390041493, 'mean_word_length': 4.962962962962963, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
High-dose-rate brachytherapy for the treatment of nonmelanoma skin cancer

Cutaneous squamous cell carcinoma (cSCC) is the second most common nonmelanoma skin cancer (NMSC) in the world,[1] and its incidence continues to rise. Surgical excision remains the most popular treatment so far due to its low recurrence rate. However, 95% of these tumors grow on the face, a major sun-exposed area. In these cases, resection would leave major defects, leading to serious cosmetic concerns.